Palisade Bio reported a pre-revenue Q3 2024 quarter (ended 2024-09-30) with no revenue and a continued burn profile characteristic of a clinical-stage biotechnology company. Key metrics show R&D intensity and general and administrative expenses driving an operating loss of $3.593 million and a net loss of $3.488 million, or an earnings per share of -$2.32. EBITDA stood at -$3.48 million. Cash burn from operations was $3.133 million for the quarter, reducing cash and equivalents to $8.07 million at period end, with no outstanding debt. The balance sheet remains lean, with minimal liabilities and a cumulative net deficit reflected in retained earnings of approximately -$132.6 million, underscoring the high-risk, high-potential nature of Palisade’s development program. Management’s near-term thesis centers on LB1148, an oral inhibitor intended to preserve gut integrity during intestinal stress, with potential value unlocked through partnerships or licensing if clinical milestones are achieved. The current liquidity provides a runway of roughly 2–3 quarters at the prevailing burn rate, implying a need for additional financing or strategic collaboration to extend operations beyond the next year.